Quince Therapeutics Doses First Subject in Ataxia-Telangiectasia Trial
Express News | Quince Therapeutics Reveals First Patient Dosed In Phase 3 Clinical Trial Of EryDex For Treatment Of Ataxia-Telangiectasia; This Pivotal Phase 3 Study Will Be Conducted Under A Special Protocol Assessment Agreement With The U.S. FDA
Express News | Quince Therapeutics Has Dosed The First Patient In Phase 3 NEAT Trial To Evaluate Neurological Effects Of EryDex In Patients With Ataxia-telangiectasia, Topline Results Are Expected In 2H Of 2025 With A Potential New Drug Application Submission In 2026
Express News | Quince Expects Phase 3 Neat Results H2 2025
Express News | Quince Therapeutics Initiates Phase 3 Trial of Erydex
Express News | Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of Erydex for the Treatment of Ataxia-Telangiectasia
FDA Fast Tracks Quince Therapeutics' Rare Ataxia Drug EryDex
Express News | FDA Grants Fast Track Designation To Quince Therapeutics' EryDex System To Treat Ataxia-Telangiectasia
Express News | Quince Therapeutics Receives U.S. FDA Fast Track Designation for Erydex System
Quince Therapeutics | 10-Q: Quarterly report
Express News | Quince Therapeutics - Expects Its Existing Cash Runway to Be Sufficient to Fund Company's Capital Efficient Development Plan Into 2026
Quince Therapeutics 1Q Loss/Shr 26c >QNCX
Quince Therapeutics 1Q Loss/Shr 26c >QNCX
Quince Therapeutics 1Q Research and Development Expenses of $3.7M >QNCX
Quince Therapeutics 1Q Research and Development Expenses of $3.7M >QNCX
Express News | Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today
Express News | Quince Therapeutics Q4 EPS $(0.21) Down From $(0.13) YoY
Quince Therapeutics Reported $75.1M in Cash as of December 31, 2023, Expect to Fully Fund Lead Asset, EryDex, Through Phase 3 NEAT Topline Results and Prepare for a Potential NDA Submission in 2026
Strong Cash Position Expected to Support Meaningful Clinical MilestoneReported $75.1 million in cash, cash equivalents, and short-term investments as of December 31, 2023. Quince expects its existing
Press Release: Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 01, 2024-- Quince Therapeutics, Inc. (Na
Quince Therapeutics Launches Scientific Advisory Board
World-renowned scientists and clinicians to provide expert insight and advice to support advancement of the company's lead Phase 3 asset, new indications, and pipeline expansion Quince Therapeutics, Inc.
Quince Therapeutics Appoints Rajiv Patni to Board of Directors